AstraZeneca moves US court against Aurobindo Pharma on generic version of patented drug Daliresp

Daliresp is a prescription medicine used in adults with severe Chronic Obstructive Pulmonary Disease

Press Trust of India May 20, 2019 08:56:45 IST
AstraZeneca moves US court against Aurobindo Pharma on generic version of patented drug Daliresp
  • AstraZeneca alleged that the Indian drug makers proposed generic Daliresp would infringe the patents on three counts

  • AstraZeneca requested the court to pass an injunction order against manufacturing, importing and selling that drug in the USA.

  • Daliresp isis a prescription medicine used in adults with severe Chronic Obstructive Pulmonary Disease

Hyderabad: Pharma major AstraZeneca has filed a petition in a US court, alleging that Aurobindo Pharma is attempting to come out with the generic version of its patented drug Daliresp (Roflumilast Tablet 500 mcg).

In a petition filed in the United States District Court for the District Court of New Jersey on 15 May, AstraZeneca alleged that the Indian drug makers proposed generic Daliresp would infringe the patents on three counts and requested the court to pass an injunction order against manufacturing, importing and selling that drug in the USA.

Daliresp isis a prescription medicine used in adults with severe Chronic Obstructive Pulmonary Disease (COPD) to decrease the number of flare-ups or the worsening of COPD symptoms (exacerbations).

AstraZeneca moves US court against Aurobindo Pharma on generic version of patented drug Daliresp

Representational image. Getty.

AstraZeneca prayed for a permanent injunction, restraining and enjoining Aurobindo Pharma from making, using, selling, offering to sell, or importing any product that infringes the 206, 064, and 142 Patent, including the product (Dalisrep).

AstraZeneca Pharmaceuticals LP is the current holder of New Drug Application for Daliresp (Roflumilast) Tablet 500 mcg, which was first approved by the Food and Drug Administration on 28 February 2011.

Aurobindo Pharma wrote to AstraZeneca Pharmaceuticals LP and AstraZeneca AB on 5 April, 2019 (Notice Letter), saying they had submitted US FDA an Abbreviated New Drug Application (ANDA ) with paragraph IV certifications for the 206, 064, and 142 Patents, the petition said.

Under this, a company can seek FDA approval to market a generic drug before the expiration of patents related to the brand-name drug that the generic seeks to copy.

A city-based pharmaceutical company senior official said patent infringement cases are not uncommon for generic drug makers in USA and the lawsuit would not have any implications on the company's performance.

Updated Date:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Emerging landscape of COVID-19 vaccines in India, as of 5 Aug: Bharat Bio, Zydus candidates move to Phase 2 after clearing test of safety
India

Emerging landscape of COVID-19 vaccines in India, as of 5 Aug: Bharat Bio, Zydus candidates move to Phase 2 after clearing test of safety

Over a dozen Indian companies are in partnership with other firms and institutes to bring a preventive vaccine into global markets by 2021.

Oxford University-AstraZeneca COVID-19 vaccine to cost Rs 225 per dose in India says Serum Institute
India

Oxford University-AstraZeneca COVID-19 vaccine to cost Rs 225 per dose in India says Serum Institute

Serum Institute partners with Gavi and Bill & Melinda Gates Foundation to manufacture, deliver of up to 100 million doses of COVID-19 vaccines to India, other low and middle-income countries.

India readies five sites for final phase of human trials of Oxford's COVID-19 vaccine
science

India readies five sites for final phase of human trials of Oxford's COVID-19 vaccine

Serum Institute of India has been chosen by Oxford University and its partner AstraZeneca to manufacture the COVID-19 vaccine